New trial of Genmab substance is symptomatic of Deborah Dunsire's Lundbeck

The study involving the Lu AF82422 antibody illustrates several of Lundbeck's recent tendencies, including attempts to ensure a higher study success rate and more substances in the company pipeline. This goes for both the approach to development and the variety of substances.

Since Deborah Dunsire joined Lunbeck three years ago, she has been hard at work getting the success rate of the company's research and development efforts back on track. | Photo: Gregers Tycho/ERH

The newly announced phase II trial with the substance Lu AF82422, which is part of a collaboration between Genmab and Lundbeck, is in many ways an example of the new research strategy that Lundbeck has created under the leadership of CEO Deborah Dunsire and Head of Research and Development Johan Luthman.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs